{"filing":{"accession_number":"0001213900-26-084247","cik":"0002023311","ticker":"AAPG","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","form":"6-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"ea0300203-6k_ascentage.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2023311/000121390026084247/ea0300203-6k_ascentage.htm"},"events":[{"id":23148,"run_id":20947,"accession_number":"0001213900-26-084247","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The company appointed Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer, both reporting directly to the CEO. These material C-suite appointments strengthen the company's leadership structure for global expansion and commercialization of its drug pipeline as multiple Phase III registrational studies advance.","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","ticker":"AAPG","filing_date":"2026-08-03","form":"6-K","submitted_at":null,"items":[{"id":23301,"accession_number":"0001213900-26-084247","item_number":"EX-99.1","item_title":"ea030020301ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The press release announces the appointment of two senior executives: Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer, both reporting directly to the CEO. These are material C-suite appointments that strengthen the company's leadership structure during a critical phase of global expansion and commercialization of its drug pipeline, particularly as multiple Phase III registrational studies advance.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:36:34.145522+00:00","company_name":"","ticker":null,"filing_date":""},{"id":23302,"accession_number":"0001213900-26-084247","item_number":"EX-99.2","item_title":"ea030020301ex99-2.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The announcement discloses the appointment of two senior executives: Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer, both reporting directly to the CEO. These are material C-suite appointments that affect the company's leadership structure and operational strategy, particularly for global business development and US commercialization functions.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:36:34.145522+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23301,"accession_number":"0001213900-26-084247","item_number":"EX-99.1","item_title":"ea030020301ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The press release announces the appointment of two senior executives: Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer, both reporting directly to the CEO. These are material C-suite appointments that strengthen the company's leadership structure during a critical phase of global expansion and commercialization of its drug pipeline, particularly as multiple Phase III registrational studies advance.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:36:34.145522+00:00","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","ticker":"AAPG","filing_date":"2026-08-03"},{"id":23302,"accession_number":"0001213900-26-084247","item_number":"EX-99.2","item_title":"ea030020301ex99-2.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The announcement discloses the appointment of two senior executives: Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer, both reporting directly to the CEO. These are material C-suite appointments that affect the company's leadership structure and operational strategy, particularly for global business development and US commercialization functions.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:36:34.145522+00:00","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","ticker":"AAPG","filing_date":"2026-08-03"}]}